Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 12.24 -0.60 (-4.67%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,315,502 Open 12.68 Bid (Size) 12.06 (4) Ask (Size) 12.99 (10) Prev. Close 12.84 Today's Range 12.13 - 12.72 52wk Range 5.120 - 14.62 Shares Outstanding 60,717,176 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference September 10, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday September 09, 2024 Via Benzinga Performance YTD +28.03% +28.03% 1 Month +39.89% +39.89% 3 Month +73.13% +73.13% 6 Month +57.94% +57.94% 1 Year -11.82% -11.82% More News Read More Analyst Ratings For Travere Therapeutics September 06, 2024 Via Benzinga Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday September 06, 2024 Via Benzinga Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease September 06, 2024 Via Investor's Business Daily Expert Ratings For Travere Therapeutics August 02, 2024 Via Benzinga Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts May 07, 2024 Via Benzinga NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday September 06, 2024 Via Benzinga Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy September 05, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 August 22, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences August 06, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024 August 02, 2024 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Travere Therapeutics Reports Second Quarter 2024 Financial Results August 01, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal July 27, 2024 Via Talk Markets Travere Therapeutics to Report Second Quarter 2024 Financial Results July 25, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire 10 Health Care Stocks Whale Activity In Today's Session July 10, 2024 Via Benzinga Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday July 09, 2024 Via Benzinga Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference July 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 11, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 15, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress May 09, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences May 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 06, 2024 Via InvestorPlace Travere Therapeutics Reports First Quarter 2024 Financial Results May 06, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report First Quarter 2024 Financial Results April 29, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
